Tropical Infections A Status Update

Introduction

Tropical diseases are the biggest killer of children and young adults globally, accounting for up to five million deaths. In many cases, treatments are available but poor economic conditions and inadequate medical facilities limit their distribution. This, in turn, limits the incentive to invest in this field, as reflected by the relatively inactive product pipeline. 

Scope

An overview of key tropical infections and the potential for products used in their treatment or prophylaxis 

Tuberculosis, malaria and dengue are profiled in terms of their definition, epidemiology and currently available vaccines and therapeutics 

Details of key pipeline products are provided and key projects analyzed in more detail 

Future outlook for tropical diseases is assessed, in terms of expanding areas of endemicity, and the market potential of future vaccines 

Report Highlights

Tropical infections cause significant morbidity and mortality especially in less-developed regions of the world. Pharmaceutical companies can contribute by research and development into novel products, such as prophylactic vaccines but it is clear the challenge lies beyond clinical efficacy of various treatments. 

Multiple public initiatives and NGO activities have focused on driving tropical infection product development forward. However, difficulty in conducting clinical studies, unpredictable logistics and co-operation from local decision makers in many developing nations still present significant barriers to all stakeholders. 

While emerging markets may not represent lucrative investment opportunities for vaccine manufacturers, estimated revenues from travel (malaria - $240m) and military markets (malaria ~$8m) may compensate. Furthermore, a visible involvement in world health may be strategic, potentially deflecting damaging criticism from cost conscious governments. 

Reasons to Purchase

Assess the potential for compounds targeting tuberculosis, malaria and dengue 

Assess the current competitive landscape for these three indications and understand key drivers and limits to demand for tropical infection products 

Identify key events associated with tropical infections during the last year 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a210